Compare ASM & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASM | AVLN |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2005 | 2026 |
| Metric | ASM | AVLN |
|---|---|---|
| Price | $4.71 | $26.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.51 | ★ $61.80 |
| AVG Volume (30 Days) | ★ 2.9M | 378.3K |
| Earning Date | 11-04-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.01 | N/A |
| Revenue Next Year | $43.25 | N/A |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $22.24 |
| 52 Week High | $11.99 | $40.17 |
| Indicator | ASM | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 50.30 |
| Support Level | N/A | $24.90 |
| Resistance Level | $6.52 | $28.52 |
| Average True Range (ATR) | 0.22 | 1.81 |
| MACD | -0.03 | 0.43 |
| Stochastic Oscillator | 6.72 | 72.83 |
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.